Edwards Lifesciences (NYSE:EW) was upgraded by research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research note issued on Thursday, Marketbeat reports. The firm presently has a $135.00 price target on the medical research company’s stock, up from their previous price target of $125.00. Barclays’ target price would suggest a potential upside of 17.61% from the stock’s current price.
A number of other equities analysts have also recently issued reports on EW. Evercore ISI assumed coverage on shares of Edwards Lifesciences in a research report on Wednesday. They set an “outperform” rating and a $140.00 target price for the company. JPMorgan Chase & Co. cut shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research report on Tuesday. Morgan Stanley cut their target price on shares of Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Canaccord Genuity restated a “buy” rating and set a $155.00 target price on shares of Edwards Lifesciences in a research report on Sunday, October 8th. Finally, BMO Capital Markets restated a “buy” rating and set a $137.00 target price on shares of Edwards Lifesciences in a research report on Friday, December 8th. Six research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $128.57.
Edwards Lifesciences (NYSE:EW) traded up $0.20 during mid-day trading on Thursday, reaching $114.79. 402,582 shares of the company were exchanged, compared to its average volume of 1,516,400. The stock has a market capitalization of $24,200.00, a P/E ratio of 33.37, a P/E/G ratio of 1.79 and a beta of 0.51. Edwards Lifesciences has a 52-week low of $86.55 and a 52-week high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.
Edwards Lifesciences declared that its Board of Directors has approved a stock repurchase program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
In other Edwards Lifesciences news, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $100.93, for a total transaction of $3,320,597.00. The disclosure for this sale can be found here. Insiders have sold 177,680 shares of company stock valued at $19,285,511 in the last ninety days. 2.13% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 2.0% during the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after buying an additional 406,901 shares during the period. BlackRock Inc. grew its stake in Edwards Lifesciences by 0.8% during the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after buying an additional 105,819 shares during the period. Wells Fargo & Company MN grew its stake in Edwards Lifesciences by 20.2% during the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after buying an additional 429,022 shares during the period. American Century Companies Inc. boosted its stake in shares of Edwards Lifesciences by 7.0% in the third quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock valued at $243,107,000 after purchasing an additional 144,701 shares during the period. Finally, Artisan Partners Limited Partnership boosted its stake in shares of Edwards Lifesciences by 12.0% in the third quarter. Artisan Partners Limited Partnership now owns 1,432,428 shares of the medical research company’s stock valued at $156,579,000 after purchasing an additional 153,896 shares during the period. Institutional investors own 81.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/04/edwards-lifesciences-ew-lifted-to-overweight-at-barclays.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.